Diverse effects of a low dose supplement of lipidated curcumin in healthy middle aged people

Robert A DiSilvestro, Elizabeth Joseph, Shi Zhao, Joshua Bomser, Robert A DiSilvestro, Elizabeth Joseph, Shi Zhao, Joshua Bomser

Abstract

Background: Curcumin extracts of turmeric are proposed to produce health benefits. To date, human intervention studies have focused mainly on people with existing health problems given high doses of poorly absorbed curcumin. The purpose of the current study was to check whether in healthy people, a low dose of a lipidated curcumin extract could alter wellness-related measures.

Methods: The present study was conducted in healthy middle aged people (40-60 years old) with a low dose of curcumin (80 mg/day) in a lipidated form expected to have good absorption. Subjects were given either curcumin (N = 19) or placebo (N = 19) for 4 wk. Blood and saliva samples were taken before and after the 4 weeks and analyzed for a variety of blood and saliva measures relevant to health promotion.

Results: Curcumin, but not placebo, produced the following statistically significant changes: lowering of plasma triglyceride values, lowering of salivary amylase levels, raising of salivary radical scavenging capacities, raising of plasma catalase activities, lowering of plasma beta amyloid protein concentrations, lowering of plasma sICAM readings, increased plasma myeloperoxidase without increased c-reactive protein levels, increased plasma nitric oxide, and decreased plasma alanine amino transferase activities.

Conclusion: Collectively, these results demonstrate that a low dose of a curcumin-lipid preparation can produce a variety of potentially health promoting effects in healthy middle aged people.

Figures

Figure 1
Figure 1
Curcumin effects on plasma triglycerides and cholesterol concentrations (mg/dl). Values are means ± SEM for N = 19 pre- and post-treatment of 4 weeks. *Significantly different from pre-value, paired t-test, p < 0.05.
Figure 2
Figure 2
Curcumin effects on plasma concentrations of nitric oxide (μM x 10) and soluble intercellular adhesion molecule (sICAM)(ng/ml). Values are means ± SEM for N = 19 pre- and post-treatment of 4 weeks. *Significantly different from pre-value, paired t-test, p < 0.05.
Figure 3
Figure 3
Curcumin effects on plasma concentrations of myeloperoxidase (ng/ml) and c-reactive protein (mg/L x 10). Values are means ± SEM for N = 19 pre- and post-treatment of 4 weeks. *Significantly different from pre-value, paired t-test, p < 0.05.
Figure 4
Figure 4
Curcumin effects on saliva activities of amylase (U/L) and antioxidant status (μM of copper reducing equivalents). Values are means ± SEM for N = 19 pre- and post-treatment of 4 weeks. *Significantly different from pre-value, paired t-test, p < 0.05.
Figure 5
Figure 5
Curcumin effects on plasma activities of catalase (U/ml) and erythrocyte superoxide dismutase (U/ml packed cells x 10-2). Values are means ± SEM for N = 19 pre- and post-treatment of 4 weeks. *Significantly different from pre-value, paired t-test, p < 0.01.
Figure 6
Figure 6
Curcumin effects on plasma activities of alanine aminotransferase (ALT) (U/L) and beta amyloid protein (pmoles/L). Values are means ± SEM for N = 19 pre- and post-treatment of 4 weeks. *Significantly different from pre-value, paired t-test, p < 0.05.

References

    1. Strimpakos A, Sharma R. Curcumin: preventive and therapeutic properties in laboratory studies and clinical trials. Food Chem Toxicol. 2008;10:511–545.
    1. Epstein J, Sanderson I, Macdonald T. Curcumin as a therapeutic agent: the evidence from in vitro, animal and human studies. Br J Nutr. 2010;103:1545–1557. doi: 10.1017/S0007114509993667.
    1. Naik S, Thakare V, Patil S. Protective effect of curcumin on experimentally induced inflammation, hepatotoxicity and cardiotoxicity in rats: evidence of its antioxidant property. Exp Toxicol Pathol. 2011;63:419–431. doi: 10.1016/j.etp.2010.03.001.
    1. Yang K, Lin L, Tseng T, Wang S, Tsai T. Oral bioavailability of curcumin in rat and the herbal analysis from curcuma Longa by LC-MS/MS. J Chromatogr B Analy Technol Biomed Life Sci. 2007;853:183–189. doi: 10.1016/j.jchromb.2007.03.010.
    1. Vareed S, Kakarala M, Ruffin M. et al.Pharmacokinetics of curcumin conjugate metabolites in healthy human subjects. Cancer Epidemiol Biomarkers Prev. 2008;17:1411–1417. doi: 10.1158/1055-9965.EPI-07-2693.
    1. Bisht S, Maitra A. Systemic delivery of curcumin: 21st century solutions for an ancient conundrum. Curr Drug Discov Technol. 2009;6:192–199. doi: 10.2174/157016309789054933.
    1. Khajehdehi P, Pakfetrat M, Javidnia K. et al.Oral supplementation of turmeric attenuates proteinuria, transforming growth factor-β and interleukin-8 levels in patients with overt type 2 diabetic nephropathy: a randomized, double-blind and placebo-controlled study. Scand J Urol Nephrol. 2011;45:365–370. doi: 10.3109/00365599.2011.585622.
    1. Pungcharoenkul K, Thongnopnua P. Effect of different curcuminoid supplement dosages on total in vivo antioxidant capacity and cholesterol levels of healthy human subjects. Phytother Res. 2011;25:1721–1726. doi: 10.1002/ptr.3608.
    1. Durgaprasad S, Pai CG, Vasanthkumar Alvres JF, Namitha S. A pilot study of the antioxidant effect of curcumin in tropical pancreatitis. Indian J Med Res. 2005;122:315–318.
    1. Sugawara J, Akazawa N, Miyaki A, Effect of endurance exercise training and curcumin intake on central arterial hemodynamics in postmenopausal women: pilot study. Am J Hypertens. 2012. in press.
    1. Arafa H. Curcumin attenuates diet-induced hypercholesterolemia in rats. Med Sci Monit. 2005;11:BR228–BR234.
    1. Rukkumani R, Aruna K, Varma P, Rajasekaran K, Menon V. Comparative effects of curcumin and its analog on alcohol- and polyunsaturated fatty acid-induced alterations in circulatory lipid profiles. J Med Food. 2005;8:256–260. doi: 10.1089/jmf.2005.8.256.
    1. Yiu W, Kwan P, Wong C. et al.Attenuation of fatty liver and prevention of hypercholesterolemia by extract of curcuma Longa through regulating the expression of CYP7A1, LDL-receptor, HO-1, and HMG-CoA reductase. J Food Sci. 2011;76:H80–H89. doi: 10.1111/j.1750-3841.2011.02042.x.
    1. Aftab N, Vieira A. Antioxidant activities of curcumin and combinations of this curcuminoid with other phytochemicals. Phytother Res. 2010;24:500–502.
    1. Iqbal M, Sharma S, Okazaki Y, Fujisawa M, Okada S. Dietary supplementation of curcumin enhances antioxidant and phase II metabolizing enzymes in ddY male mice: possible role in protection against chemical carcinogenesis and toxicity. Pharmacol Toxicol. 2003;92:33–38. doi: 10.1034/j.1600-0773.2003.920106.x.
    1. Kempaiah R, Srinivasan K. Antioxidant status of red blood cells and liver in hypercholesterolemic rats fed hypolipidemic spices. Int J Vitam Nutr Res. 2004;74:199–208. doi: 10.1024/0300-9831.74.3.199.
    1. Thresiamma K, George J, Kuttan R. Protective effect of curcumin, ellagic acid and bixin on radiation induced toxicity. Indian J Exp Biol. 1996;34:845–847.
    1. Eybl V, Kotyzova D, Koutensky J. Comparative study of natural antioxidants curcumin, resveratrol and melatonin - in cadmium-induced oxidative damage in mice. Toxicology. 2006;225:150–156. doi: 10.1016/j.tox.2006.05.011.
    1. Ataie A, Sabetkasaei M, Haghparast A, Moghaddam A, Kazeminejad B. Neuroprotective effects of the polyphenolic antioxidant agent, curcumin, against homocysteine-induced cognitive impairment and oxidative stress in the rat. Pharmacol Biochem Behav. 2010;96:378–385. doi: 10.1016/j.pbb.2010.06.009.
    1. Zhang C, Browne A, Child D, Tanzi R. Curcumin decreases amyloid-beta peptide levels by attenuating the maturation of amyloid-beta precursor protein. J Biol Chem. 2010;285:28472–28480. doi: 10.1074/jbc.M110.133520.
    1. Hamaguchi T, Ono K, Yamada M. Curcumin and Alzheimer's disease. CNS Neurosci Ther. 2010;16:285–297. doi: 10.1111/j.1755-5949.2010.00147.x.
    1. DiSilvestro RA, Marten JT. Effects of inflammation and copper intake on rat liver and erythrocyte Cu-Zn superoxide dismutase activity levels. J Nutr. 1990;120:1223–1227.
    1. Hirooka Y, Kishi T, Sakai K. Imbalance of central nitric oxide and reactive oxygen species in the regulation of sympathetic activity and neural mechanisms of hypertension. Am J Physiol Regul Integr Comp Physiol. 2011;300:R818–R826. doi: 10.1152/ajpregu.00426.2010.
    1. Tang W, Pankow JS, Carr JJ. Association of sICAM-1 and MCP-1 with coronary artery calcification in families enriched for coronary heart disease or hypertension: the NHLBI Family Heart Study. BMC Cardiovasc Disord. 2007;7:30. doi: 10.1186/1471-2261-7-30.
    1. Nauseef WM. How human neutrophils kill and degrade microbes: an integrated view. Immunol Rev. 2007;219:88–102. doi: 10.1111/j.1600-065X.2007.00550.x.
    1. Zhang R, Brennan ML, Fu X. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA. 2001;286:2136–2142. doi: 10.1001/jama.286.17.2136.
    1. Calabrò P, Golia E, Yeh E. CRP and the risk of atherosclerotic events. Semin Immunopathol. 2009;31:79–94. doi: 10.1007/s00281-009-0149-4.
    1. Rohleder N, Nater U. Determinants of salivary alpha-amylase in humans and methodological considerations. Psychoneuroendocrinology. 2009;34:469–485. doi: 10.1016/j.psyneuen.2008.12.004.
    1. Moro M, Collins M, Cappellini E. Alzheimer's disease and amyloid beta-peptide deposition in the brain: a matter of 'aging'? Biochem Soc Trans. 2010;38:539–544. doi: 10.1042/BST0380539.
    1. Craxı A, Almasio P. Diagnostic approach to liver enzyme elevation. J Hepatol. 1996;25S:47–51.
    1. Nanji AA, Jokelainen K, Tipoe G, Rahemtulla A, Thomas P, Dannenberg AJ. Curcumin prevents alcohol-induced liver disease in rats by inhibiting the expression of NF-kB-dependent genes. Am J Physiol Gastrointest Liver Physiol. 2003;284:G321–G327.
    1. Almeida JA, Riordan SM, Liu J, Galhenage S, Kim R, Bihari D, Wegner EA, Cranney GB, Thomas PS. Deleterious effect of nitric oxide inhibition in chronic hepatopulmonary syndrome. Eur J Gastroenterol Hepatol. 2007;19:341–346. doi: 10.1097/MEG.0b013e328014a3bf.
    1. Girish C, Koner B, Jayanthi S, Ramachandra Rao K, Rajesh B, Pradhan S. Hepatoprotective activity of picroliv, curcumin and ellagic acid compared to silymarin on paracetamol induced liver toxicity in mice. Fundam Clin Pharmacol. 2009;23:735–745. doi: 10.1111/j.1472-8206.2009.00722.x.
    1. Balaji S, Chempakam B. Toxicity prediction of compounds from turmeric (curcuma Longa L) Food Chem Toxicol. 2010;48:2951–2959. doi: 10.1016/j.fct.2010.07.032.
    1. Baum L, Cheung SK, Mok VC, Lam LC, Leung VP, Hui E, Ng CC, Chow M, Ho PC, Lam S, Woo J, Chiu HF, Goggins W, Zee B, Wong A, Mok H, Cheng WK, Fong C, Lee JS, Chan MH, Szeto SS, Lui VW, Tsoh J, Kwok TC, Chan IH, Lam CW. Curcumin effects on blood lipid profile in a 6-month human study. Pharmacol Res. 2007;56:509–514. doi: 10.1016/j.phrs.2007.09.013.
    1. Srivastava R, Singh S, Dubey S, Misra K, Khar A. Immunomodulatory and therapeutic activity of curcumin. Int Immunopharmacol. 2011;11:331–341. doi: 10.1016/j.intimp.2010.08.014.
    1. Ak T, Gülçin I. Antioxidant and radical scavenging properties of curcumin. Chem Biol Interact. 2008;174:27–37. doi: 10.1016/j.cbi.2008.05.003.
    1. Ramos MP, Madrigal MJ, Martinez PR. et al.Proteomic analysis of polymorphonuclear neutrophils identifies catalase as a novel biomarker of abdominal aortic aneurysm: potential implication of oxidative stress in abdominal aortic aneurysm progression. Arterioscler Thromb Vasc Biol. 2011;31:3011–3019. doi: 10.1161/ATVBAHA.111.237537.
    1. Biswas J, Sinha D, Mukherjee S, Roy S, Siddiqi M, Roy M. Curcumin protects DNA damage in a chronically arsenic-exposed population of West Bengal. Hum Exp Toxicol. 2010;29:513–524. doi: 10.1177/0960327109359020.

Source: PubMed

3
Subscribe